Earnings Preview For PennyMac Financial Servs

PennyMac Financial Servs (NYSE:PFSI) is set to give its latest quarterly earnings report on Thursday, 2024-02-01. Here’s what…

PennyMac Financial Servs (NYSE:PFSI) is set to give its latest quarterly earnings report on Thursday, 2024-02-01. Here’s what investors need to know before the announcement.

Analysts estimate that PennyMac Financial Servs will report an earnings per share (EPS) of $1.49.

PennyMac Financial Servs bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company beat EPS by $0.08, which was followed by a 8.57% increase in the share price the next day.

Here’s a look at PennyMac Financial Servs’s past performance and the resulting price change:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate 1.69 1.49 0.97 1.15
EPS Actual 1.77 1.11 0.57 0.93
Price Change % 8.57% -5.11% -5.2% -8.63%

eps graph

Stock Performance

Shares of PennyMac Financial Servs were trading at $89.26 as of January 30. Over the last 52-week period, shares are up 22.1%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

To track all earnings releases for PennyMac Financial Servs visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Prelude Therapeutics Reports FY23 Financial Results And Outlines Key Objectives For 2024; FY23 EPS $(2.02) Vs $(2.44) YoY; Current Cash Runway Into 2026 With $232.9M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2023

First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in

PRLD